 |
41 Diseases |  |
16 Trials |
|
16 Trials |  |
501 News |  |
| «12345678 |
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Enrollment open, Circulating tumor cells, Tumor cell: CALM-NET: Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients (clinicaltrials.gov) - Apr 28, 2014
P4, N=50, Recruiting, Sponsor: Ipsen
Not yet recruiting --> Recruiting
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
New P4 trial, Circulating tumor cells, Tumor cell: CALM-NET: Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients (clinicaltrials.gov) - Feb 27, 2014
P4, N=50, Recruiting, Sponsor: Ipsen
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Biomarker: TAPAS: Predictive Factors Study (clinicaltrials.gov) - Dec 23, 2013
P=N/A, N=34, Not yet recruiting, Sponsor: Ipsen
- ||||| Signifor LAR (pasireotide long acting release) / Recordati, Sandostatin LAR Depot (octreotide acetate) / Novartis
Enrollment closed: PAOLA: Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly (clinicaltrials.gov) - Nov 12, 2013
P3, N=190, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- || Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Trial completion: MEDARD: Lanreotide Autogel in the Symptomatic Treatment of Refractory Diarrhea (clinicaltrials.gov) - Oct 6, 2013
P2/3, N=42, Completed, Sponsor: Ipsen
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Trial completion: Non Interventional Post Marketing Programme in Neuroendocrine Tumours (clinicaltrials.gov) - Oct 6, 2013
P=N/A, N=40, Completed, Sponsor: Ipsen
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Trial completion: LEAD: Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects (clinicaltrials.gov) - Oct 6, 2013
P4, N=124, Completed, Sponsor: Ipsen
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Enrollment change: NET729: Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour (clinicaltrials.gov) - Aug 28, 2013
P3, N=89, Active, not recruiting, Sponsor: Ipsen
Active, not recruiting --> Completed N=140 --> 89
- ||||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Enrollment closed: NET729: Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour (clinicaltrials.gov) - Aug 28, 2013
P3, N=89, Active, not recruiting, Sponsor: Ipsen
N=140 --> 89 Enrolling by invitation --> Active, not recruiting
- ||||||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Trial completion: CLARINET: Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours (clinicaltrials.gov) - Aug 28, 2013
P3, N=264, Completed, Sponsor: Ipsen
Enrolling by invitation --> Active, not recruiting Active, not recruiting --> Completed
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
New P2 trial: SOMATULINE Autogel 90 mg IN DUMPING SYNDROME (clinicaltrials.gov) - Aug 13, 2013
P2, N=25, Recruiting, Sponsor: Universitaire Ziekenhuizen Leuven
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Enrollment open: SOMATULINE Autogel 90 mg IN DUMPING SYNDROME (clinicaltrials.gov) - Aug 12, 2013
P2, N=25, Recruiting, Sponsor: Universitaire Ziekenhuizen Leuven
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- || Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Enrollment change: SODA: Somatuline (clinicaltrials.gov) - Jun 18, 2013
P=N/A, N=200, Recruiting, Sponsor: Ipsen
Not yet recruiting --> Recruiting N=160 --> 200
- ||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Trial completion: One Year Follow-up of Study 2-79-52030-207 (PRIMARYS) in Acromegalic Patients With Macroadenoma (clinicaltrials.gov) - Jun 18, 2013
P=N/A, N=54, Completed, Sponsor: Ipsen
N=160 --> 200 Enrolling by invitation --> Completed
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
New P4 trial, Surgery: A Pilot Study of Pre- and Post-operative Use of Somatuline Depot. (clinicaltrials.gov) - May 22, 2013
P4, N=24, Recruiting, Sponsor: John Wayne Cancer Institute
- ||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Biomarker, Enrollment open: SOPRANo: Somatuline Predictive Factors in Acromegaly and NET (clinicaltrials.gov) - Apr 24, 2013
P=N/A, N=152, Recruiting, Sponsor: Ipsen
Enrolling by invitation --> Completed Not yet recruiting --> Recruiting
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Trial completion: Non Interventional Post Marketing Programme in Acromegaly (clinicaltrials.gov) - Apr 21, 2013
P=N/A, N=42, Completed, Sponsor: Ipsen
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Enrollment closed: ELECT: An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome (clinicaltrials.gov) - Feb 25, 2013
P3, N=115, Active, not recruiting, Sponsor: Ipsen
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Trial completion: SYMNET: A Study to Assess Neuroendocrine Tumour (NET) Patients Currently Treated by Somatuline Autogel for History of Carcinoid Syndrome Associated With Episodes of Diarrhea (clinicaltrials.gov) - Jan 30, 2013
P=N/A, N=340, Completed, Sponsor: Ipsen
Recruiting --> Active, not recruiting Recruiting --> Completed
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Enrollment open: Lanreotide Autogel Treatment of Patients With Congenital Hyperinsulinism of Infancy (clinicaltrials.gov) - Dec 11, 2012
P4, N=10, Recruiting, Sponsor: Sheba Medical Center
Recruiting --> Completed Not yet recruiting --> Recruiting
- || Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
New P3 trial: DIPAK1: Study of Lanreotide to Treat Polycystic Kidney Disease (clinicaltrials.gov) - Jun 10, 2012
P3, N=300, Recruiting, Sponsor: University Medical Centre Groningen
- ||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Enrollment open: SODA: Somatuline (clinicaltrials.gov) - Apr 29, 2012
P=N/A, N=200, Recruiting, Sponsor: Ipsen
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen
Enrollment open: Influence of Somatuline Autogel 120mg on Post-operative Drainage After Total Mesorectum Excision for Rectumcarcinoma (clinicaltrials.gov) - Feb 29, 2012
P3, N=50, Recruiting, Sponsor: University Hospital, Ghent
Active, not recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Trial completion: PRIMARYS: Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma (clinicaltrials.gov) - Feb 29, 2012
P3, N=108, Completed, Sponsor: Ipsen
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Enrollment change: PRIMARYS: Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma (clinicaltrials.gov) - Nov 28, 2011
P3, N=108, Completed, Sponsor: Ipsen
Active, not recruiting --> Completed N=90 --> 108
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Enrollment change: Non Interventional Post Marketing Programme in Neuroendocrine Tumours (clinicaltrials.gov) - Sep 19, 2011
P=N/A, N=40, Completed, Sponsor: Ipsen
N=90 --> 108 N=50 --> 40